| Variable | All patients (n = 54) |
| Male sex, n (%) | 23 (42.6%) |
| Ex-smoker, n (%) | 6 (11.1%) |
| Age (years) | 42.5 (13.7) |
| Asthma duration (years) | 24.9 (16.6) |
| Positive IgE serology (%) | 89% |
| Median (IQR) equivalent beclometasone daily dose (μg) | 400 (200–800) |
| Morning PEF (l/min) | 390.3 (103.5) |
| Evening PEF (l/min) | 403.3 (101.4) |
| FEV1 pre-salbutamol (l) | 2.78 (0.86) |
| FEV1 post-salbutamol (l) | 3.18 (0.84) |
| FEV1 (% predicted) | 85.7 (19.3) |
| FEV1 (% reversibility) | 14.9 (11.7) |
| Geometric mean (range) PC20 (mg/ml) | 2.5 (0.9–6.2) |
| ACQ score | 1.5 (0.8) |
| AQLQ score, median (IQR) | 5.75 (5.03–6.19) |
ACQ, Asthma Control Questionnaire; AQLQ, Asthma Quality of Life Questionnaire; FEV1, forced expiratory volume in 1 s; PC20, concentration of methacholine that reduces the FEV1 by 20%; PEF, peak expiratory flow.
Data represented as mean (SD) unless otherwise indicated.